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Amplification and up-regulation of MIR30D
was associated with disease progression of
cervical squamous cell carcinomas
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Abstract
Background: Cervical squamous cell carcinoma (CSCC) is the most frequent type among cervical cancers. Although
the altered miRNA miR-30d expression and the amplified chromosome locus of MIR30D, 8q24, have been reported
in somatic cancers, the definitive functional impact of such region especially in CSCC remains under-investigated.
Methods: One hundred thirty-six cases of CSCC tissues and matched adjacent normal ovarian epithelial tissues
were assessed in this study. FISH and qPCR were performed to detect the copy number and microRNA expression
of MIR30D gene in the collected samples. In in-vitro study, proliferation of CSCC cells were analyzed using WST-1
assay and invasion abilities of CSCC cells were evaluated by transwell assay. In-vivo study using a model of nude
mice bearing tumor was also performed.
Results: Copy number gains of MIR30D were detected in 22.8% (31 out of 136) of CSCC samples. Copy number of
MIR30D was positively correlated with tumor progression. CSCCs with lymph node metastases (LNM) also showed
more frequencies (36.4%) of MIR30D amplification than those without LNM (18.4%, p < 0.05). CSCCs with increased
copy number of MIR30D also showed a positive correlation with miR-30d up-regulation. Inhibition of miR-30d in
CSCC cells led to impaired tumor growth and migration.
Conclusions: Copy number amplifications of MIR30D gene and enhanced expression of miR-30d were positively
correlated with tumor progression in CSCCs, indicating miR-30d might play an oncomiric role in the progression of
CSCC.
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Background
Invasive cervical cancer is one of the leading causes of
cancer-related death in gynecological tumors [1–4]. The
exploration of new strategies for diagnoses, treatment,
and prognoses of cervical squamous cell carcinomas
(CSCCs) merit special attention [5]. About 80% to 90%
of cervical cancers are squamous cell carcinomas [6, 7],
where the abnormal squamous cells develop and cover
the surface of the cervix. Although 80%–95% of women
with early-stage CSCC could benefit from traditional
surgery and chemoradiotherapy, it remains hard to re-
duce the recurrence- and metastasis-related cancer
death [8–10].
MicroRNAs (miRNAs) are a class of short non-
coding RNAs that negatively regulate the expression
of their protein-coding mRNA targets [11, 12]. Up to
now, thousands of miRNAs in human have been dis-
covered. Despite their relatively limited number, each
individual miRNA can alter the expression of hun-
dreds of targeted mRNAs [13]. Therefore, miRNAs
are considered as major regulators of many important
biological processes including apoptosis, viral infec-
tion and cancer development [14–17]. Whole genome
analyses showed that approximately half of miRNA
coding genes lie in fragile sites or in tumor-associated
genomic regions [18]. Recently, dys-regulation of
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microRNA expression has been found to be one of
the abnormal events during the development of cer-
vical cancer [19–21].
miR-30d is fairly frequently overexpressed in many hu-
man epithelial cancers and functionally affects various
tumor biological events such as proliferation, differenti-
ation, metastasis, apoptosis, etc. [22–25]. Consistently,
the chromosome locus of MIR30D gene, 8q24, is also
found frequently amplified by comparative genomic
hybridization (CGH) detection in various types of som-
atic cancers [26, 27].
Although overexpression of miR-30d in cervical can-
cers was reported in a previous study using a high
throughput assay [28], the case number was very limited
(n = 10). Importantly, the clinical significance of miR-
30d in the progression of cervical cancers remains
under-investigated. In this research, 136 sporadic CSCC
tumor samples and their matched adjacent normal tis-
sues (ANTs) were collected from a Chinese population.
Copy number variations (CNVs) of MIR30D gene as well
as expression levels of miR-30d were examined, and ana-
lyzed with clinical characterization. In-vitro studies were
also performed to estimate the role of miR-30d in the
cell proliferation and migration of CSCCs. Our findings
showed that amplified copy number of the MIR30D gene
and/or up-regulated expression of miR-30d were posi-
tively correlated with CSCC disease progression, indicat-
ing that miR-30d plays as a critical oncomir in CSCC
progression and could be a potential biomarker and
therapeutic target for CSCCs.
Methods
Patients and tissue collection
Samples were taken from CSCC patients at the
Department of gynecology and obstetrics, Peking
University Shenzhen Hospital from June 2008 to July
2014. A summary of cohort characteristics was shown
in Table 1. Tumors were staged according to the clas-
sification system: Stage 0 (The carcinoma is confined
to the surface layer of the cervix; not included be-
cause it cannot be distinguished from CIN3), Stage 1
(The carcinoma has grown deeper into the cervix, but
has not spread beyond it, n = 35), Stage 2 (Cervical
carcinoma invades beyond the uterus, but not to the
pelvic wall or to the lower third of the vagina,
n = 78, IIa = 47, IIb = 31), Stage 3 (The tumor
extends to the pelvic wall and/or involves lower third
of the vagina and/or causes hydro-nephrosis or non-
functioning kidney, n = 16) and Stage 4 (The carcin-
oma has extended beyond the true pelvis or has
involved (biopsy proven) the mucosa of the bladder
or rectum, n = 7). Cases under Stage IIa (including
IIa) were grouped into early-stage, whose samples
were collected from surgery. Cases above IIb
(including IIb) were grouped into advanced stage and
received radiotherapy and chemotherapy, whose sam-
ples were collected from biopsy. The matched ANTs
were defined as tissues located at least 1.5 cm far
from the macroscopically unaffected margins of the
tumor. The samples without qualified ANTs were ex-
cluded. All samples were rapidly frozen in liquid ni-
trogen immediately after excision and were stored in
liquid nitrogen until use.
RNA extraction and quantitative real-time PCR (qPCR)
Total RNA from tissues or cell lines was isolated in ac-
cordance with the manufacturer’s instruction of the Axy-
Prep™ Blood Total RNA MiniPrep Kit (Axygen). Then
the first-strand cDNA was synthesized by reverse tran-
scription with the RevertAid™ First Strand cDNA
Synthesis Kit (Fermentas). And the primer for reverse
transcription of miR-30d is: 5′-GTC GTA TCC AGT
GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG
ACC TTC CA-3′.
Bio-Rad iQ™ SYBR Green Supermix real-time PCR
kit and CFX96 Detection System was used to perform
qPCR. The quantitative primer pair for miR-30d is:
forward: 5′-GCA TTG TAA ACA TCC CCG AC-3′,
and reverse: 5′- GTG CAG GGT CCG AGG TAT
TC-3′. Melt curves were produced for product identi-
fication and purity at the end point of PCR cycles.
Because of the near-100% amplification efficiencies of
all targeted genes, qPCR results were calculated using
2−ΔΔct method. miR-30d expression level in each
sample was analyzed using Bio-Rad CFX Manager
Table 1 Summary of the cohort characteristics
Characteristics Information
Age Average age 49.8
Range 18 ~ 71
Risk factors Multiple sex partners 55
Multiparous or pregnant at youth 26
First sex before 18 19
None of above 36










Smoking history Yes 21
No 115
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software and normalized to the expression of U6. The
expression levels of the target miRNAs or mRNAs
were visually identified using exploratory data analysis
with scatter plots [29]. Each quantitative reaction was
replicated twice, and the average value was used in
the scatter plot. Other primer pairs for the targeted
mRNA are listed in Table 2.
DNA extraction and quantification of copy numbers
The method of copy number calculation has been in-
troduced previously [30, 31]. Genomic DNA was pre-
pared from tissues following the protocol of the
Genomic DNA Extraction Kit (Innocent, Shenzhen,
China). Quantitative PCR was performed through Bio-
Rad CFX96 Detection System. The relative copy num-
bers of MIR30D were normalized to RNAse P gene
(copy numbers =2) and analyzed by the comparative
Ct method. The copy numbers as 0, 1, 2 and 3 were
respectively defined by cut-off values of 0.25, 0.75,
1.25 and 1.75. The primer pair, forward: 5′-GAT GAT
GAC TGG CAA CAT-3′ and reverse: 5′-GAA TAG
CCG GTA GCA GCA-3′, was used for the detection
of MIR30D. And the primer pair for RNAse P is: for-
ward: 5′-AGA CTA GGG TCA GAA GCA A-3′ and
reverse: 5′-CAT TTC ACT GAA TCC GTT C-3′.
The relative copy number fold-change was calculated
using the 2−ΔΔCt method.
Fluorescence in situ hybridization (FISH) analysis
CSCC tissues and matched ANTs were collected in
pairs as stated before, and ten pairs (5 with MIR30D
amplification, 5 with unaltered MIR30D copy number)
were selected for FISH analysis. The tissue was
minced into single-cell suspension with a scalpel after
treatment with 0.075 M KCl for 10 min. Then the
cell suspension was fixed in a fixative (3:1 ratio of
methanol and acetic acid). Target slides were prepared
by dropping the suspension of isolated fixed nuclei
on a glass slide, and slides were fixed in 70 °C steam
and denatured in 2× SSC/70% formamide, pH 7, at
75 °C for 5 min and dehydrated in graded ethanol.
FISH detections were performed with dual-labeling
hybridization using a directly labeled centromere probe
for chromosome 8 (Spectrum Green-labeled) together
with a probe for the MIR30D locus (8q24.22; Spectrum
Orange-labeled). After denatured at 75 °C for 5 min,
probes were hybridized onto the target slides overnight
at 37 °C. Then these slides were washed with 50% form-
amide/2× SSC for 10 min three times, 2× SSC for 5 min,
and 2× SSC/NP40 for 5 min at 45 °C. After washing, the
slides were counterstained with 1 μg/ml DAPI, and sig-
nals for each locus-specific FISH probe were assessed
using an Olympus microscope equipped with a triple
band pass filter. At least 300 nuclei were examined in
each sample. FISH signals were counted and recorded as
0, 1, 2, 3, 4, 5, or more signals for each probe.
Cell culture and proliferation assay
Human cervical cancer cell lines HeLa, C4–1, SiHa, Caski
and C-33A were obtained from the Cobioer Biosciences
Co., Ltd. (Shanghai, China) and grown in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco) supplemented
with 10% FBS (PAA) and 1% penicillin/streptomycin (Life
Technologies, Inc.) at 37 °C and 5% CO2.
WST-1 measurement was used to detect cell prolifera-
tion. Cells transfected with mimic, inhibitor or non-
sense strand were seeded onto 96-well culture plates
with 1 × 103 cells per well, The proliferation of cells was
tested using the colorimetric reagent WST-1 (Roche) at
different time points (0, 1, 2, 3, 4, and 5 days).
Cell invasion assay
Invasion assays were done using 24-well transwell cham-
bers (8 μm pore size; BD Biosciences). After incubation
with 1% BSA for 1 h at 37 °C, transwells were coated
with fibronectin (10 mg/ml in PBS) overnight at 4°C.
Meanwhile, SiHa and HeLa cells were transfected with
miR-30d mimic, inhibitor or control strand for 24 h.
Then the cells were collected by trypsin-EDTA digestion,
washed once in 10% FBS/DMEM, and resuspended in
1% FBS/DMEM at 2 × 105 cells/ml. And the cell suspen-
sions were equivalently added to the upper compartment
of each chamber (100 μl per chamber). Following 12 h
incubation, the non-invaded cells on the upper surface
of the membrane were removed with a cotton swab,
whereas the cells that had invaded through the mem-
brane to the underside surface were fixed by 3% formal-
dehyde and stained with 0.3% crystal violet for 10 min.
The cells on the underside of the membrane were
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counted and the number of cells in five different fields
(×100 magnification) was used to quantify cell invasion.
Data represent the average ± SD of three independent
experiments.
Retroviral transduction
Each retroviral vector and the pLC 10A1 retroviral pack-
aging vector (Imgenex, San Diego, CA, USA) was co-
transfected into HEK293T cells using the Lipofectamine
LTX reagent (Invitrogen). After 24 h, the conditioned
medium was collected as a viral solution. The retroviral
vectors were infected into the cells in the medium that
contained 10 μg/mL polybrene (Sigma, St. Louis, MO,
USA) and allowed to incubate for 24 h. Then, the viable
cells were selected using 800 μg/mL neomycin (G418;
Invitrogen). The selected pooled clones were used in the
biological analyses. The transfection efficiency was deter-
mined using qPCR analysis.
Generation of the in vivo xenograft model
Five-week-old male nude mice were used in this study.
Subconfluent HeLa and SiHa cells were transduced with
miR-30d-blocking or control viral vectors, trypsinized,
and suspended in Phosphate-buffered saline (PBS). Then,
the cells were subcutaneously injected into the right (to
inhibit miR-30d) and left (control) flanks of the same
mice. HeLa was subcutaneously injected at a concentra-
tion of 1 × 106 cells. SiHa cells were subcutaneously
injected as a mixture of 2 × 106 cells and an equal volume
of Matrigel (BD Biosciences), reaching a total concentra-
tion of 10 mg/mL (15 mice each group). Tumor growth
was followed for 42 days after tumor cell injection. Mori-
bund animals were euthanized according to the protocols
of the Peking University Health Science Center. Each
xenograft tumor volume was calculated using the follow-
ing formula: tumor volume = (short axis2 × long axis)/2.
Gene expression studies
Gene expression profiles were obtained by using
Affymetrix GeneChip® Probe Arrays. According to the
manufacturer’s instructions, the total RNA was isolated
from each sample (prewashed by 50 mM potassium
phosphate buffer, pH 7.4) with RNeasy Mini Kit
(Qiagen). And Bioanalyzer 2100 (Agilent Technologies,
Fig. 1 Relative expression of miR-30d in CSCCs. qPCR assay was carried out as described under Materials and Methods section, and the results
were obtained from the indicated group of samples. a Scatterplot illustrated the relative expression level of miR-30d as a ratio of miR-30d to U6
in all the CSCC samples compared with ANTs. b Scatterplot illustrated the relative expression of miR-30d as a ratio of CSCC to paired ANT in the
CSCCs at different stages. c Scatterplot illustrated the relative expression of miR-30d as a ratio of CSCC to paired ANT in the primary tumors and
lymph node metastases. d Kaplan-Meier and log-rank analysis (n = 136). The 2 groups were divided according to the expression levels of miR-30d
(over-expression group, T/N ≥ 2, n = 57; mid or low expression group, n = 79) and analyzed (P = 0.0009; log-rank test) to determine its association
with biochemical recurrence in CSCC
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US) was applied to confirm the quality of extracted
RNA. The DNA microarray data were was produced by
Bio Matrix Research (Chiba, Japan).
GeneSpring software package (Agilent Technologies,
US) was used for statistical analysis, and online tools
of the Munich Information Center for Protein
Sequence (MIPS) was used for the pathway- or
function-based classification. Gene expression data
have been submitted to the Gene Expression Omni-
bus (GEO; http://www.ncbi.nlm.nih.gov/geo).
Statistical analysis
The categorical data were analyzed for statistical signifi-
cance by chi-square test or Fisher exact test, or analysis
of variance (ANOVA). All the above mentioned analyses
were performed using GraphPad Prism 5.0 statistical
software and p-values less than 0.05 were considered
statistically significant.
Results
Enhanced expression of miR-30d in CSCCs was correlated
with tumor progression
The transcriptional expression of miR-30d was evaluated
using qPCR. Compared to ANTs, the expression levels
of miR-30d were markedly enhanced in the collected
CSCC samples (p < 0.001), as shown in Fig. 1a. In
addition, there were statistically higher expression level
of miR-30d in the group of advanced CSCCs (n = 54)
than early-stage CSCCs (n = 82, p = 0.0037, Fig. 1b).
To further investigate the role of miR-30d abnormalities
in the spread of CSCCs, we compared the expression of
miR-30d between primary tumors and metastases isolated
from 21 cases with qualified paired lymph node metastasis
samples (≦IIa, from surgery). As shown in Fig. 1c, paired
t-test analyses showed that metastatic CSCCs had a slight
but statistically significant increase of miR-30d expression,
in comparison with primary tumors (p = 0.0392).
To explore the clinical significance of altered miR-30d
expression levels, the intracellular miR-30d expression
were scored as overexpression (CSCC/ANT ≧2, n = 59)
and moderate or low expression (n = 77). It showed that,
increased expression level of mature miR-30d had very
significant correlation with poor clinical outcomes in
CSCC patients (Fig. 1d, P =0.0013).
Gene copy number gains of MIR30D in CSCC samples
As shown in Table 3, distribution of MIR30D copy num-
ber in ANTs had no statistical difference in comparison
to healthy normal controls (HNCs), and thus the ANTs
could be used by the present study as matched controls
for the CSCC tissues.
In a total of 136 matched samples of CSCC patients,
we had examined the CNVs of MIR30D in cancer tissues
and ANTs (Table 4). Copy number gains of MIR30D
gene were found in a portion of CSCC tissues (22.8%, 31
out of 136). Much higher frequencies of MIR30D gene
amplification were observed in the advanced CSCCs
(31.6% for stage3–4) than those in early-stage CSCCs
(16.5% for stage 0–2). These results indicated that copy
number gains of MIR30D gene were positively correlated
with CSCCs tumor progression (p < 0.01).
In the collected CSCC cases, 33 out of 136 showed
LNM. We next analyzed the copy number of MIR30D in
the CSCCs with or without LNM. As shown in Table 5,
36.4% of CSCC cases with LNM showed MIR30D ampli-
fication, which was much higher than those without
LNM (18.4%, p = 0.0327). However, in the 21 CSCC
cases with qualified lymph node samples, only 2 cases
showed increased MIR30D copy number in LNMs
compared to the primary tumors while others had no
differences between the LNMs and primary sites.
Table 3 Comparison of CNVsa of MIR30D between adjacent
normal tissues and healthy normal controls
Samples n Copy number P
(vs. HNC)Deletion Amplification
0 1 2 3 >3
HNCa 168 1 7 155 3 2 —
ANTa 136 2 1 127 4 2 0.747
aCNV copy number variation, ANT adjacent normal tissue, HNC healthy
normal control
Table 4 CNVsa of MIR30D gene in CSCC tissues and matched ANTsa
Population Number Copy numbers P (vs. ANT) P (vs. early-
stage CSCC)Deletion or Unalteration Amplification
≦2 >2
Total ANT 136 130 6 — —
CSCC 105 31 9.79E-06 —
Early-stage (0-IIa) ANT 82 80 2 — —
CSCC 68 14 2.83E-3 —
Stage 3–4 (IIb-IV) ANT 54 50 4 — —
CSCC 38 17 8.92 E-4 0.038
aCNV copy number variation, CSCC cervical squamous cell carcinoma, ANT adjacent normal tissue
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Nevertheless, MIR30D amplifications might play a role in
CSCC metastasis.
In order to verify the CNVs of MIR30D gene in
CSCCs, paraffin-embedded CSCC tissues and matched
ANT tissues were picked out (n = 10, 5 amplification, 5
unaltered) to conduct a reexamination by FISH analysis
with chromosome 8q and 8q24 specific probe (MIR30D).
The obtained results showed highly consistence with
those from the qPCR experiments (Fig. 2 and Table 6).
Positive correlation between amplifications of MIR30D
gene and miR-30d up-regulation in CSCCs
Gene CNVs are frequently associated with the quanti-
tative as well as functional shift of their gene prod-
ucts. We then tested whether the expression levels of
miR-30d were correlated with gene copy alterations
in several selected samples with amplified or un-
altered copies of MIR30D gene. As in Fig. 3, in both
groups with amplified or unaltered copies of MIR30D,
the CSCC tissues showed significantly higher expres-
sion of miR-30d than ANTs (p < 0.005). It’s interest-
ing that the CSCC samples of MIR30D amplified
group showed a statistical difference of miR-30d
expression compared to unaltered group (p = 0.019).
Hence, to some extent DNA copy amplifications were
the driving force of the up-regulation of miR-30d in
CSCCs.
miR-30d plays an oncomiric role in CSCC cells
Although miR-30d was considered as an oncomir in
various kinds of epithelial cancer [24, 32, 33], it has
also been reported that miR-30d suppresses cell pro-
liferation and motility and induces apoptosis in sev-
eral types of tumors [34, 35]. In order to determine
the role of miR-30d in CSCC, multiple corresponding
cell lines including HeLa, C4–1, SiHa, Caski and
C-33A were first evaluated for miR-30d expression.
HeLa and SiHa showed relatively higher expression of
miR-30d (Fig. 4a), and thus were selected for the fol-
lowing knockdown experiments.
After transfected with the mimic or inhibitor of
miR-30d, the expressions of miR-30d in the above
cell lines were significantly altered (Fig. 4b). The
effect of altered expression of miR-30d on CSCC cell
proliferation was estimated by WST-1 assay. As
shown in Fig. 4c, the expression of miR-30d was
Table 5 CNVsa of MIR30D gene in CSCCs with or without LNM
Population Number Copy numbers P (vs. ANT) P (vs. early-
stage CSCC)Deletion or Unalteration Amplification
≦2 >2
Total ANT 136 130 6 — —
CSCC 105 31 9.79E-06 —
Without LNM ANT 103 99 4 — —
CSCC 84 19 1.95E-3 —
With LNM ANT 33 31 2 — —
CSCC 21 12 6.73E-3 0.0327
aCNV copy number variation, LNM lymph node metastasis, CSCC cervical squamous cell carcinoma, ANT adjacent normal tissue
Fig. 2 Gene amplification of MIR30D in CSCCs. Representative figures of FISH analysis using chromosome 8q specific alpha satellite DNA probe
and chromosome 8q24 specific probe for MIR30D. a Nucleus of ANT tissue with two signals for each of green and red, showing no amplification
of chromosome 8q or MIR30D gene; b Nucleus of CSCC tissue with normal signals for green and multiple signals for red, indicating relative amplification
in chromosome 8q24 or MIR30D gene
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positively correlated with proliferation rates of the
CSCC cells.
Next, the migration abilities of HeLa and SiHa cells
transfected with miR30d mimic, inhibitor or non-sense
strand were estimated by the trans-well assay. A positive
correlation between miR-30d expression and CSCC cell
migration was also observed (Fig. 4d). Thus, enhanced
expression of miR-30d might play a role in the progres-
sion of CSCCs.
To evaluate the functional effects of miR-30d in
vivo, we established 2 CSCC cell lines (HeLa and
SiHa) that stably suppressed miR-30d expression via
retroviral transduction. These miR-30d-suppressed cell
lines were subcutaneously injected into the right side
of male nude mice; control CSCC cell lines were
simultaneously injected into the left side (15 mice
each group). The representative xenograft mice and
xenografted tumors were shown in Fig. 4e and f, re-
spectively. At sacrifice, the mean volumes of tumor
xenografts from the nude mice were measured (Table 7),
which showed that the CSCC cells with suppressed ex-
pression of miR-30d formed significantly smaller tumor
nodules compared with the controls. The attenuation of
miR-30d expression in these xenografts were also con-
firmed by qPCR (Fig. 4g). Taken together, these results
suggest that up-regulation of miR-30d may promotes
CSCC cell proliferation and migration contributing to
tumor progression and metastasis.
miR-30d regulates the expression of a number of genes
in CSCCs
Since a single miRNA can regulate tens or hundreds of
targeted mRNA, so even though the expression status of
only one single miRNA was altered, cells may undergo a
great phenotypic change. Oncomiric role of miR-30d
would be performed by transforming multiple signaling
pathways rather than by disturbing one or a few cancer-
associated genes. After the transfection of a miR-30d
mimic into HeLa and SiHa cells, microarray analyses
were used to display the transcriptional changes.
Over-expression of miR-30d down-regulated 464 and
376 genes in HeLa and SiHa cells, respectively [see
Additional files 1 & 2].
Bioinformatics methods were used to analyze the
possible direct targets of miR-30d. By TargetScan
(http://www.targetscan.org/), 131 of 464 down-regulated
genes in HeLa and 117 of 376 in SiHa were predicted as
targets of miR-30d (Fig. 5a). These data suggested that
about 30% of those downregulated transcripts were indeed
directly repressed by miR-30d. Moreover, about 1/3
(n = 129) down-regulated genes were shared in both cell
lines, and 68 of these were TargetScan predicted targets of














1 2 − − − − 0.97
2 3 − − − − 1.03
3 3 − − − − 0.92
4 3 − − − − 1.15
5 4 − − − − 1.02
MIR30D amplification 6 2 + − − − 16.75
7 3 + − − + 8.48
8 4 + + − − 3.62
9 4 + − − − 22.43
10 4 + + − − 9.67
Fig. 3 MIR30D amplification leads to overexpression of miR-30d.
Scatterplot illustrated the relative expression level of miR-30d as a ratio
of miR-30d to U6 in the groups with or without MIR30D amplification
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miR-30d [see Additional file 3]. Notably, several known
miR-30d targets identified by other groups, including
ATG12 [25], CASP3 [32], SNAI1 [36], SOCS1 [24],
FOXO3 [34] and GNAI2 [37], were consistently found in
our 68 transcript list. Finally, 10 of these genes were se-
lected and further verified by qPCR in HeLa and SiHa
cells, as well as another 2 independent cell lines, C4–1
and Caski (Fig. 5b). Taken together, these results indicate
that miR-30d directly affects the expression of a number
of genes in CSCC to play its oncomiric role.
Fig. 4 miR-30d acts as an oncomir in CSCCs. a Expression levels of miR-30d were examined by real-time PCR; b After treatment of miR-30d inhibitor,
mimic and control strand, the expression levels of miR-30d were examined by real-time PCR. The relative expression of miR-30d is illustrated as a ratio to
control (U6); c WST-1 (Roche) assay measuring the activity of mitochondrial dehydrogenases was performed following the manufacturer’s instruction at 0-,
1-, 2-, 3-, 4- day time points. The results were obtained from three independent experiments. Error bars represent the standard deviation of the mean; d
Cell migration was determined using a transwell assay as described in the Materials and methods section. Microscopic image of migrated HeLa and SiHa
cells with indicated treatments. Diagrams of migrating cells from the different transfectants are shown, which are from more than three independent
experiments.*p < 0.05 versus control. e-f Tumor growth indicates the stable inhibition of miR-30d expression in CSCC cell lines when subcutaneously
injected into the right (inhibitor of miR-30d) and left (control) flanks of male nude mice (n = 15). Tumor growth was followed for 42 after tumor cell
injection. The dotted line represents the tumor mass. g Expression of miR-30d extracted from xenografts using qPCR. The expression level
of miR-30d was normalized to the expression state of U6. Values represent the means, and the error bars represent the SD. *p < 0.05 according
to the paired t-test
Table 7 Mean final volume of xenografts when nude mice
sacrificed
SiHa (mm3) HeLa (mm3)
Control (n = 15) 892.037 ± 329.843 496.234 ± 219.317
miR-30d suppressed (n = 15) 342.902 ± 152.035 204.298 ± 98.953
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Discussion
Besides identification and functional annotation of
miRNAs, investigation of transcriptional regulation of
miRNA genes should also be one of the notable is-
sues. In the present study, we found that copy num-
ber variation also played a role in the dysregulated
expression of cancer-microRNA in CSCCs. The am-
plifications of MIR30D (22.8%, 31 out of 136) were
found in collected CSCC samples. Given that no stat-
istical difference of MIR30D CNVs between HNCs
and ANTs was observed, the CNVs of MIR30D were
more likely to acquire aberrations in CSCC tumor tis-
sues. However, the frequency of MIR30D gene copy
number gain was lower than previously reported pro-
portions of chromosomes 8q24 gain as 36–57% in
somatic cancers [7, 38, 39]. This discrepancy might be
due to the limited region of MIR30D gene on chromo-
some 8q24 which is less influenced by repeated replication
during tumor progression. Amplifications of MIR30D
were mainly found in advanced CSCCs, indicating that
the increase of MIR30D copies might occur in the pro-
gression but not the initiation of CSCCs and may contrib-
ute to tumor aggressiveness. We also found that CSCCs
with LNM showed more frequencies of MIR30D amplifi-
cation than those without LNM, which indicated the po-
tential association between MIR30D amplification and
CSCC metastasis. Interestingly, in 2 cases with LNM, we
found that the copy numbers of MIR30D were increased
in LNMs compared to primary tumor. Did the copy num-
ber gain of MIR30D take place in migrating cells at the
initiation of metastasis or later in the lymph node in these
2 cases? This needs further investigation.
Microarray-based comparative genomic hybridization
(aCGH) analyses have shown that CNVs may directly or
indirectly make a healthy body susceptible to cancer by
altering the expression of oncogenes or tumor suppres-
sor genes. Detection of the CNVs status is just a starting
point for investigations into the role of such gene alter-
ations in the development of cervical cancer. However,
there are many discrepancies among the results obtained
from the previous high-throughput studies of CNVs.
Therefore, it is necessary to validate these CNVs in a
large number of clinical samples. Furthermore, the de-
tection sensitivity could also be improved by using se-
quence specific quantitative PCR to examine short DNA
fragments of hundreds of base pairs.
Fig. 5 miR-30d regulates various kinds of cancer-related genes. a Venn diagrams of transcript numbers shared by downregulated transcripts in
miR-30d mimic transfections in HeLa and SiHa cells and predicted targets of miR-30d by TargetScan. b The microarray results were validated by
real-time RT-PCR in 4 tumor cells. qPCR validation of transcripts that were downregulated in both HeLa and SiHa cells after transfection with the
miR-30d mimic and that were also predicted miR-30d targets by TargetScan. Validations were done in SiHa and HeLa cells, as well as in 2 independent
cell lines, C4–1 and Caski., *p < 0.05
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Although it has been thought that cell phenotype is
well correlated with the genotype of CNVs [40, 41], our
study on the correlation between expression of miR-30d
and copy numbers of MIR30D gene showed discordant
findings. Compared to ANTs, the expression of miR-30d
in CSCC tissues was increased in both groups with or
without MIR30D amplification. Thus CNVs were not
the only motivating factor for over-expression of the
miR-30d in CSCCs. Some other mechanisms could be
involved in the transcriptional regulation of miRNA ex-
pression. For instance, CpG island hyper-methylation
have been reported to be involved in the regulation of
miR-30d expression in somatic malignancies.
In the in-vitro and in-vivo studies, we showed that
amplification and up-regulation of miR-30d promoted
CSCC growth and metastasis, which further indicated
the important role of miR-30d de-regulation in the pro-
gression of CSCC. As a non-coding RNA, miR-30d must
mediate its tumor-promoting role through suppression
of special targets. Here we also screened several key tar-
gets of miR-30d that might be involved in this progress.
In the genes suppressed by miR-30d over-expression,
most are tumor-suppressing genes that were down-
regulated by miR-30d transfection. However, several
target genes, such as CCNE2 and SNAI1, are positively
correlated with tumorigenesis. These indicated the com-
plex role of microRNAs in influencing tumorigenesis.
Conclusions
To summarize, our results demonstrate that the amplifi-
cation of MIR30D copy number were present in a cer-
tain proportion of CSCC cases and were positively
correlated with its transcriptional expression as well as
progression of tumor. Enhanced expression of miR-30d
plays an oncomiric role in CSCC through the regulation
of various cancer-related genes.
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